menu toggle

HTA Quarterly | Winter 2021

By Xcenda

In this issue, we examine NICE's 5-year strategy and their focus on collaborative engagement,  the German assessment process for digital health applications and the importance of prospective studies, and the use of telehealth in value-based care models.

Globe with communication lines from UK

HTA Quarterly | Winter 2021

Is NICE becoming nicer?

From fourth hurdle to firm handshake, we consider how NICE’s 5-year strategy signals a shift from adversarial to collaborative engagement and how stakeholders can benefit.
Heart on mobile phone

HTA Quarterly | Winter 2021

Evidence generation and approval of digital health applications in Germany

Digital health applications (DiGA) offer great opportunities for improving healthcare for patients. With the enactment of the Digital Healthcare Act (DVG), millions of individuals covered by the German Statutory Health Insurance (SHI) are eligible for DiGA coverage. A standardized assessment process has been developed to ensure the effectiveness of DiGA. This article provides an overview of the German assessment process and highlights the importance of prospective studies in the evaluation process.
Laptop and data

HTA Quarterly | Winter 2021

Telehealth through the lens of value-based care in the US

With the advance of technology and increasing needs of an aging population, telehealth has been playing an important role in transforming the delivery of healthcare. The ongoing coronavirus disease (COVID-19) pandemic and the expansion of value-based care (VBC) models have also contributed to its rapid adoption in the US. Telehealth can facilitate data-driven decision making and has great potential to assist providers, biopharmaceutical companies, and medical device manufacturers in reducing uncertainty in demonstrating the value of their products.

HTA by the numbers

WHO recommended a groundbreaking malaria vaccine for children. Over 260,000 children under the age of 5 die in Africa from malaria annually; the vaccine provides 30% reduction in deadly severe malaria.

Heard on the Street

speech bubble icon
“The pandemic has permanently shifted how CADTH—and other health technology assessment agencies—conducts its work… This year we have seen ultra-rapid assessments of new technologies; increased use of uncertain, evolving, and real-world evidence; and greater national and international coordination and collaboration. These have not only defined 2020–2021, but they are also becoming the new norm.”
– Suzanne McGurn, President and CEO, Canadian Agency for Drugs and Technologies in Health (CADTH)